To treat osteoporosis, denosumab appears more effective than zoledronate: denosumab has the advantage in building bone density, and has fewer side effects.: An article from: Duke Medicine Health News

This digital document is an article from Duke Medicine Health News, published by Belvoir Media Group, LLC on March 1, 2014. The length of the article is 914 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: To treat osteoporosis, denosumab appears more effective than zoledronate: denosumab has the advantage in building bone density, and has fewer side effects.
Author: Susan E. Spratt
Publication:Duke Medicine Health News (Newsletter)
Date: March 1, 2014
Publisher: Belvoir Media Group, LLC
Volume: 20 Issue: 3 Page: 1(2)

Distributed by Gale, a part of Cengage Learning